| Richard Hehner, MD | |
|
3505 S Reed Rd, Kokomo, IN 46902-3838 | |
| (765) 453-8666 | |
| Not Available |
| Full Name | Richard Hehner |
|---|---|
| Gender | Male |
| Speciality | Legal Medicine |
| Location | 3505 S Reed Rd, Kokomo, Indiana |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144220302 | NPI | - | NPPES |
| 100345060 | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 01031250A (Indiana) | Secondary |
| 173000000X | Legal Medicine | 1031250 (Indiana) | Primary |
| Entity Name | Woodlawn Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639241227 PECOS PAC ID: 4082506993 Enrollment ID: O20040326000043 |
News Archive
Anavex Life Sciences Corp. ("Anavex") (OTCBB: AVXL) has announced that its clinical trial application (CTA) for ANAVEX 2-73, the company's lead compound for Alzheimer's disease, has been approved by the German regulatory health authority, BfArM. The Phase I trial of ANAVEX 2-73, which includes testing in healthy human volunteers, will commence immediately. In this Phase I program Anavex will assess the safety, maximally tolerated dose, pharmacokinetics and pharmacodynamics of ANAVEX 2-73.
A blood vessel-blocking drug called tasquinimod slowed the rate of disease progression in a clinical trial of 200 prostate cancer patients, according to experts at Johns Hopkins, Roswell Park Cancer Institute and Duke University.
David Woods, the current president of PENTAX Medical of the Americas, has been appointed as the new global Chief Marketing Officer (CMO), effective April 1, 2015...
IRIDEX Corporation announced the introduction of its new XP Module - a high power factory installed option for the IRIDEX IQ 532 green laser system.
Melinda Gates, co-chair of the Bill & Melinda Gates Foundation, and New York Times columnist Nicholas Kristof continue to answer readers' questions in this second installment on Kristof's "On the Ground" blog.
› Verified 2 days ago
| Entity Name | Emergency Professionals Of Indiana Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013951219 PECOS PAC ID: 4183604150 Enrollment ID: O20040721000612 |
News Archive
Anavex Life Sciences Corp. ("Anavex") (OTCBB: AVXL) has announced that its clinical trial application (CTA) for ANAVEX 2-73, the company's lead compound for Alzheimer's disease, has been approved by the German regulatory health authority, BfArM. The Phase I trial of ANAVEX 2-73, which includes testing in healthy human volunteers, will commence immediately. In this Phase I program Anavex will assess the safety, maximally tolerated dose, pharmacokinetics and pharmacodynamics of ANAVEX 2-73.
A blood vessel-blocking drug called tasquinimod slowed the rate of disease progression in a clinical trial of 200 prostate cancer patients, according to experts at Johns Hopkins, Roswell Park Cancer Institute and Duke University.
David Woods, the current president of PENTAX Medical of the Americas, has been appointed as the new global Chief Marketing Officer (CMO), effective April 1, 2015...
IRIDEX Corporation announced the introduction of its new XP Module - a high power factory installed option for the IRIDEX IQ 532 green laser system.
Melinda Gates, co-chair of the Bill & Melinda Gates Foundation, and New York Times columnist Nicholas Kristof continue to answer readers' questions in this second installment on Kristof's "On the Ground" blog.
› Verified 2 days ago
| Entity Name | App Of Indiana Ed, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740822212 PECOS PAC ID: 2961835400 Enrollment ID: O20191213001639 |
News Archive
Anavex Life Sciences Corp. ("Anavex") (OTCBB: AVXL) has announced that its clinical trial application (CTA) for ANAVEX 2-73, the company's lead compound for Alzheimer's disease, has been approved by the German regulatory health authority, BfArM. The Phase I trial of ANAVEX 2-73, which includes testing in healthy human volunteers, will commence immediately. In this Phase I program Anavex will assess the safety, maximally tolerated dose, pharmacokinetics and pharmacodynamics of ANAVEX 2-73.
A blood vessel-blocking drug called tasquinimod slowed the rate of disease progression in a clinical trial of 200 prostate cancer patients, according to experts at Johns Hopkins, Roswell Park Cancer Institute and Duke University.
David Woods, the current president of PENTAX Medical of the Americas, has been appointed as the new global Chief Marketing Officer (CMO), effective April 1, 2015...
IRIDEX Corporation announced the introduction of its new XP Module - a high power factory installed option for the IRIDEX IQ 532 green laser system.
Melinda Gates, co-chair of the Bill & Melinda Gates Foundation, and New York Times columnist Nicholas Kristof continue to answer readers' questions in this second installment on Kristof's "On the Ground" blog.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Richard Hehner, MD 3505 S Reed Rd, Kokomo, IN 46902-3838 Ph: (765) 453-8666 | Richard Hehner, MD 3505 S Reed Rd, Kokomo, IN 46902-3838 Ph: (765) 453-8666 |
News Archive
Anavex Life Sciences Corp. ("Anavex") (OTCBB: AVXL) has announced that its clinical trial application (CTA) for ANAVEX 2-73, the company's lead compound for Alzheimer's disease, has been approved by the German regulatory health authority, BfArM. The Phase I trial of ANAVEX 2-73, which includes testing in healthy human volunteers, will commence immediately. In this Phase I program Anavex will assess the safety, maximally tolerated dose, pharmacokinetics and pharmacodynamics of ANAVEX 2-73.
A blood vessel-blocking drug called tasquinimod slowed the rate of disease progression in a clinical trial of 200 prostate cancer patients, according to experts at Johns Hopkins, Roswell Park Cancer Institute and Duke University.
David Woods, the current president of PENTAX Medical of the Americas, has been appointed as the new global Chief Marketing Officer (CMO), effective April 1, 2015...
IRIDEX Corporation announced the introduction of its new XP Module - a high power factory installed option for the IRIDEX IQ 532 green laser system.
Melinda Gates, co-chair of the Bill & Melinda Gates Foundation, and New York Times columnist Nicholas Kristof continue to answer readers' questions in this second installment on Kristof's "On the Ground" blog.
› Verified 2 days ago